S&P 500   3,347.84 (-0.38%)
DOW   27,822.17 (+0.11%)
QQQ   267.85 (-0.91%)
AAPL   440.30 (-2.36%)
MSFT   204.98 (-1.57%)
FB   260.12 (-1.10%)
GOOGL   1,494.53 (-0.15%)
AMZN   3,106.98 (-1.31%)
NVDA   436.12 (-2.35%)
CGC   17.32 (-3.40%)
BABA   248.69 (+0.23%)
TSLA   1,379.00 (-2.79%)
GE   6.73 (+0.75%)
MU   48.53 (-1.26%)
AMD   77.28 (-6.03%)
T   30.45 (+0.83%)
F   7.25 (+2.26%)
ACB   10.13 (-0.98%)
GILD   68.12 (-0.57%)
NFLX   471.39 (-2.48%)
DIS   130.93 (+1.66%)
BAC   27.05 (+1.85%)
BA   182.12 (+1.51%)
S&P 500   3,347.84 (-0.38%)
DOW   27,822.17 (+0.11%)
QQQ   267.85 (-0.91%)
AAPL   440.30 (-2.36%)
MSFT   204.98 (-1.57%)
FB   260.12 (-1.10%)
GOOGL   1,494.53 (-0.15%)
AMZN   3,106.98 (-1.31%)
NVDA   436.12 (-2.35%)
CGC   17.32 (-3.40%)
BABA   248.69 (+0.23%)
TSLA   1,379.00 (-2.79%)
GE   6.73 (+0.75%)
MU   48.53 (-1.26%)
AMD   77.28 (-6.03%)
T   30.45 (+0.83%)
F   7.25 (+2.26%)
ACB   10.13 (-0.98%)
GILD   68.12 (-0.57%)
NFLX   471.39 (-2.48%)
DIS   130.93 (+1.66%)
BAC   27.05 (+1.85%)
BA   182.12 (+1.51%)
S&P 500   3,347.84 (-0.38%)
DOW   27,822.17 (+0.11%)
QQQ   267.85 (-0.91%)
AAPL   440.30 (-2.36%)
MSFT   204.98 (-1.57%)
FB   260.12 (-1.10%)
GOOGL   1,494.53 (-0.15%)
AMZN   3,106.98 (-1.31%)
NVDA   436.12 (-2.35%)
CGC   17.32 (-3.40%)
BABA   248.69 (+0.23%)
TSLA   1,379.00 (-2.79%)
GE   6.73 (+0.75%)
MU   48.53 (-1.26%)
AMD   77.28 (-6.03%)
T   30.45 (+0.83%)
F   7.25 (+2.26%)
ACB   10.13 (-0.98%)
GILD   68.12 (-0.57%)
NFLX   471.39 (-2.48%)
DIS   130.93 (+1.66%)
BAC   27.05 (+1.85%)
BA   182.12 (+1.51%)
S&P 500   3,347.84 (-0.38%)
DOW   27,822.17 (+0.11%)
QQQ   267.85 (-0.91%)
AAPL   440.30 (-2.36%)
MSFT   204.98 (-1.57%)
FB   260.12 (-1.10%)
GOOGL   1,494.53 (-0.15%)
AMZN   3,106.98 (-1.31%)
NVDA   436.12 (-2.35%)
CGC   17.32 (-3.40%)
BABA   248.69 (+0.23%)
TSLA   1,379.00 (-2.79%)
GE   6.73 (+0.75%)
MU   48.53 (-1.26%)
AMD   77.28 (-6.03%)
T   30.45 (+0.83%)
F   7.25 (+2.26%)
ACB   10.13 (-0.98%)
GILD   68.12 (-0.57%)
NFLX   471.39 (-2.48%)
DIS   130.93 (+1.66%)
BAC   27.05 (+1.85%)
BA   182.12 (+1.51%)
Log in

NASDAQ:FIXXHomology Medicines Stock Price, Forecast & News

$11.22
-1.42 (-11.23 %)
(As of 08/11/2020 03:22 PM ET)
Add
Compare
Today's Range
$10.30
Now: $11.22
$12.50
50-Day Range
$12.51
MA: $14.83
$16.59
52-Week Range
$11.05
Now: $11.22
$24.00
Volume45,380 shs
Average Volume672,172 shs
Market Capitalization$507.26 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.12
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Read More
Homology Medicines logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FIXX
CUSIPN/A
Phone781-301-7277

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.67 million
Book Value$5.73 per share

Profitability

Net Income$-103,920,000.00
Net Margins-5,816.28%

Miscellaneous

Employees124
Market Cap$507.26 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$11.22
-1.42 (-11.23 %)
(As of 08/11/2020 03:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

How has Homology Medicines' stock been impacted by COVID-19?

Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FIXX stock has decreased by 37.1% and is now trading at $11.26.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Homology Medicines?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Homology Medicines
.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Homology Medicines
.

How were Homology Medicines' earnings last quarter?

Homology Medicines Inc (NASDAQ:FIXX) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.78) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.04. Homology Medicines had a negative return on equity of 44.92% and a negative net margin of 5,816.28%.
View Homology Medicines' earnings history
.

What price target have analysts set for FIXX?

7 Wall Street analysts have issued 1 year price objectives for Homology Medicines' stock. Their forecasts range from $27.00 to $34.00. On average, they expect Homology Medicines' share price to reach $30.43 in the next year. This suggests a possible upside of 170.2% from the stock's current price.
View analysts' price targets for Homology Medicines
.

Has Homology Medicines been receiving favorable news coverage?

Media stories about FIXX stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Homology Medicines earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Homology Medicines
.

Are investors shorting Homology Medicines?

Homology Medicines saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 4,630,000 shares, an increase of 13.8% from the July 15th total of 4,070,000 shares. Based on an average daily trading volume, of 480,400 shares, the days-to-cover ratio is presently 9.6 days. Currently, 15.7% of the company's stock are sold short.
View Homology Medicines' Short Interest
.

Who are some of Homology Medicines' key competitors?

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), NVIDIA (NVDA), Alector (ALEC), Canopy Growth (CGC), Inovio Pharmaceuticals (INO) and Heron Therapeutics (HRTX).

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the following people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)
  • Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 50)
  • Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63)

When did Homology Medicines IPO?

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by many different retail and institutional investors. Top institutional shareholders include Bessemer Group Inc. (0.17%), Swiss National Bank (0.12%), Russell Investments Group Ltd. (0.10%), Aigen Investment Management LP (0.07%), New York State Common Retirement Fund (0.07%) and American Investment Services Inc. (0.07%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am and W Bradford Smith.
View institutional ownership trends for Homology Medicines
.

Which major investors are buying Homology Medicines stock?

FIXX stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Aigen Investment Management LP, Swiss National Bank, Rafferty Asset Management LLC, ProShare Advisors LLC, Russell Investments Group Ltd., Leap Investments LP, and WINTON GROUP Ltd.
View insider buying and selling activity for Homology Medicines
.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $11.26.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $509.06 million and generates $1.67 million in revenue each year. The company earns $-103,920,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.

What is Homology Medicines' official website?

The official website for Homology Medicines is www.homologymedicines.com.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.